Keya Medical

Executive Summary

Keya Medical, founded in 2016 and headquartered in Seattle, is a private medical AI company focused on non-invasive cardiovascular diagnostics. Its flagship product, DEEPVESSEL FFR, is an AI-powered software that analyzes coronary CT angiograms to compute fractional flow reserve (FFRCT). This tool aids in the precise diagnosis of coronary artery disease, potentially reducing unnecessary invasive procedures, improving patient safety, and lowering healthcare costs. Keya Medical’s technology represents a shift toward augmentative AI in clinical decision-making, aligning with the growing demand for cost-effective, non-invasive diagnostic alternatives. The company operates in the competitive landscape of AI-driven diagnostics, with peers like HeartFlow, but differentiates through its proprietary algorithms and focus on integration into existing clinical workflows. As a private entity, Keya Medical has not disclosed funding or valuation, but its presence in the medtech hub of Seattle and its regulatory progress signal potential for growth. The company’s success hinges on achieving regulatory clearances, building clinical evidence, and securing partnerships with healthcare providers and imaging centers. With the global burden of cardiovascular disease and the push for AI in healthcare, Keya Medical is well-positioned to capture market share, though it faces challenges in reimbursement and adoption.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Next-Generation DEEPVESSEL FFR75% success
• Q4 2026Publication of Pivotal Clinical Study Results in Peer-Reviewed Journal60% success
• Q1 2027Strategic Partnership with Major Hospital Network or Imaging Provider50% success